Insulet (NASDAQ:PODD) Upgraded at StockNews.com

Insulet (NASDAQ:PODD) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday.

Several other research analysts have also commented on the company. JPMorgan Chase & Co. raised their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. TD Cowen raised their target price on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Stifel Nicolaus upped their price target on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday. Wells Fargo & Company increased their price objective on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Sanford C. Bernstein assumed coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $289.06.

Insulet Trading Up 0.2 %

Shares of NASDAQ:PODD traded up $0.68 during trading on Monday, reaching $283.48. 864,954 shares of the stock were exchanged, compared to its average volume of 582,464. The firm’s 50-day moving average price is $273.33 and its 200 day moving average price is $248.46. The firm has a market cap of $19.88 billion, a price-to-earnings ratio of 48.96, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23. Insulet has a 12-month low of $160.19 and a 12-month high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. On average, sell-side analysts anticipate that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

Hedge funds and other institutional investors have recently made changes to their positions in the business. QRG Capital Management Inc. bought a new stake in Insulet during the 3rd quarter valued at $297,000. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Insulet by 30.1% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock valued at $2,192,000 after purchasing an additional 1,942 shares during the period. Fisher Asset Management LLC raised its stake in shares of Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after purchasing an additional 3,113 shares in the last quarter. Orion Portfolio Solutions LLC lifted its holdings in Insulet by 86.2% in the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock worth $1,822,000 after purchasing an additional 3,623 shares during the period. Finally, Nomura Asset Management Co. Ltd. grew its position in Insulet by 5.7% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock valued at $35,708,000 after buying an additional 8,301 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.